コンテンツへスキップ
Merck
すべての画像(1)

Key Documents

View All Documentation

安全性情報

719900

Sigma-Aldrich

Resomer® RG 504 H、ポリ(D,L-ラクチド-co-グリコリド)

acid terminated, lactide:glycolide 50:50, Mw 38,000-54,000

別名:

PLGA

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

化学式:
[C3H4O2]x[C2H2O2]y
CAS番号:
26780-50-7
UNSPSCコード:
12162002
NACRES:
NA.23

品質水準

200

形状

amorphous

原料比

lactide:glycolide 50:50

分子量

Mw 38,000-54,000

劣化の時間枠

<3 months

粘度

0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

転移温度

Tg 46-50 °C

保管温度

2-8°C

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI Key

LCSKNASZPVZHEG-UHFFFAOYSA-N

アプリケーション

Resomer® RG 504 H, ポリ(D,L-ラクチド-co-グリコリド)を用いて、 局所的な血餅形成を促進するトロンビンの安全かつ局所的に制御された放出のための 生分解性止血デバイスを作製することができます。

CuOをカプセル化して刺激応答性多機能ナノキャリアを形成するためのポリマーナノスフェアの調製に使用できます。

法的情報

Evonik社の製品です。
RESOMER is a registered trademark of Evonik Rohm GmbH

関連製品

製品番号
詳細
価格

911593

NanoFabTx™ microfluidic - nano, device kit for synthesis of 100-200 nm nanoparticles and liposomes

911860

NanoFabTx™ microfluidic - micro, device kit for synthesis of 1-5 μm particles

911879

NanoFabTx™ microfluidic - micro, device kit for synthesis of 10-30 μm particles

909637

NanoFabTx™ PLGA-nano, for synthesis of 100 and 200 nm particles

912212

NanoFabTx™ PLGA-micro, for synthesis of 10-30 um particles

912220

NanoFabTx™ PLGA-micro, for synthesis of 1-5 μm particles

920436

NanoFabTx™ PEG-PLA drug formulation screening kit, for synthesis of PEGylated nanoparticles

915408

NanoFabTx™ PEGylated nanoparticle formulation screening kit

917796

NanoFabTx™ PEG-PLGA drug formulation screening kit, for synthesis of PEGylated nanoparticles

918881

NanoFabTx™ PEG-PCL drug formulation screening kit, for synthesis of PEGylated nanoparticles

918075

NanoFabTx™ PLA-nano, for synthesis of 100 and 200 nm particles

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

719900-1G:
719900-VAR:
719900-BULK:
719900-5G:

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number
BCCG3293
BCCD7787
BCCC6288
BCCB0093
BCBX4108

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Hossein Kamali et al.
Materials science & engineering. C, Materials for biological applications, 96, 561-575 (2019-01-05)
An in situ forming gel (ISFG) of buprenorphine (BP) was prepared using PLGA-PEG-PLGA (triblock) and N‑methyl‑2‑pyrrolidone as solvent for decreasing the initial burst release. Supercritical CO2 method was used for ring opening polymerization of triblock. The optimum formulation of ISFG
Niranjan G Kotla et al.
Nanomaterials (Basel, Switzerland), 9(9) (2019-09-05)
There is a pressing clinical need for advanced colon-specific local drug delivery systems that can provide major advantages in treating diseases associated with the colon, such as inflammatory bowel disease (IBD) and colon cancer. A precise colon targeted drug delivery
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or
Vanna Sanna et al.
International journal of nanomedicine, 7, 5501-5516 (2012-10-25)
Resveratrol, like other natural polyphenols, is an extremely photosensitive compound with low chemical stability, which limits the therapeutic application of its beneficial effects. The development of innovative formulation strategies, able to overcome physicochemical and pharmacokinetic limitations of this compound, may
関連する文献をすべて表示

資料

Poly(Glycerol Sebacate) in Tissue Engineering and Regenerative Medicine

The world of commercial biomaterials has stagnated over the past 30 years as few materials have successfully transitioned from the bench to clinical use. Synthetic aliphatic polyesters have continued to dominate the field of resorbable biomaterials due to their long history and track record of approval with the U.S. Food and Drug Administration (FDA).

Biodegradable Polyester-based Nanoparticle Formation by Miniemulsion Technique

Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.

Biodegradable Polyester-based Nanoparticle Formation by Miniemulsion Technique

Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.

Biodegradable Polyester Based Nanoparticle Formation by Miniemulsion Technique

Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.

すべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）